Type 2 diabetes mellitus (T2DM) continues its alarming spread worldwide, requiring effective and sustainable therapeutic interventions. Over the past decade, the pharmaceutical realm has introduced new classes of drugs aiming to address various facets of this multifaceted disorder. Among them, SGLT2 inhibitors have carved a niche for themselves, standing out for their unique mechanism of action focused on renal glucose reabsorption. The incorporation of SGLT2 inhibitors has undeniably enriched the therapeutic options for T2DM. While they introduce novel benefits, it's imperative for clinicians to stay vigilant about potential adverse effects. A judicious approach, involving regular monitoring and patient education, is key to optimizing the use of these agents in diabetes care
Copyright © 2024 AWINSA Life Sciences Pvt. Ltd. All rights reserved.
59 E,Shrewsbury Place
Princeton, NJ 08540
United States
E13/9 First floor, Vasant Vihar,
New Delhi 110057
Wilhelmina Druckerlaan 10,
6532 SR,
Nijmegen,
The Netherlands
Cerrada Ahuizotla 53,
Col. Santiago Ahuizotla,
Del. Azcapotzalco
CP.02750
Ciudad de México, México.
